Gastrointestinal Cancer

Disease Group

Gastrointestinal Cancer

Disease Group Profile

The GI Oncology Disease Group has a highly collaborative team of investigators who are committed to developing innovative therapeutic strategies for patients with significant, unmet need. We have launched disease-specific umbrella trials to identify patients with actionable molecular targets and treat those patients with best-in-class therapies. Moving forward, the GI team hopes to leverage its strengths to expand its portfolio of targets and therapies.

Disease Group Leaders

Tanios Bekaii-Saab, M.D.

ACCRU Chair, Board of Directors ChairMayo Clinic Arizona

Tanios Bekaii-Saab, M.D. is a medical oncologist focusing on the treatment of gastrointestinal malignancies. He is the leader of the gastrointestinal cancer program for the Mayo Clinic Enterprise Cancer Center. Dr. Bekaii-Saab has served on various committees for ACCRU since 2012. He currently serves as the Consortium and Board of Director Chair for ACCRU.

John Strickler, M.D.

Duke University Medical Center

John Strickler, M.D. is an Associate Professor at Duke University, where he is the Associate Director of Clinical Research – GI Oncology and Co-Leader of the Molecular Tumor Board. Dr. Strickler’s clinic specializes on the treatment of gastrointestinal malignancies, with a particular emphasis on colorectal cancer.

Disease Group Clinical Trials